New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
04:55 EDTAGN, AGN, AGN, AGN, AGN, SHPG, SHPG, SHPG, SHPG, SHPG, REGN, REGN, REGN, REGN, REGN, PFE, PFE, PFE, PFE, PFE, ALXN, ALXN, ALXN, ALXN, ALXN, MRK, MRK, MRK, MRK, MRK, AZN, AZN, AZN, AZN, AZN, BMY, BMY, BMY, BMY, BMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
News For AGN;SHPG;REGN;PFE;ALXN;MRK;AZN;BMY From The Last 14 Days
Check below for free stories on AGN;SHPG;REGN;PFE;ALXN;MRK;AZN;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 4, 2014
09:02 EDTMRKMerck's relebactam granted QIDP, fast track designations by FDA
Merck announced that the U.S. Food and Drug Administration has designated relebactam -- previously known as MK-7655 -- the companys investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Relebactam is an investigational, class A and C, beta-lactamase inhibitor that is being evaluated in combination with imipenem/cilastatin in ongoing Phase 2 clinical trials for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. In preclinical studies, relebactam administered in combination with imipenem/cilastatin demonstrated antibacterial activity against a broad range of Gram-negative and beta-lactam-resistant pathogens. Merck plans to initiate Phase 3 studies with relebactam in combination with imipenem/cilastatin in 2015.
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:23 EDTAZN, PFEAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
07:21 EDTMRKMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
05:37 EDTREGNRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 3, 2014
19:04 EDTALXNNICE recommends commissioning of Eculizumab for patients with aHUS in England
Subscribe for More Information
17:25 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
12:19 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
11:30 EDTPFEPfizer has conference call hosted by Bernstein
Subscribe for More Information
05:44 EDTAZNTeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
09:07 EDTAGNAllergan filed answer in federal court reponding to Valeant, Pershing claims
Subscribe for More Information
08:05 EDTAGNAllergan says Ozurdex apporved in EU for treatment of diabetic macular edema
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information
07:12 EDTBMYCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
07:10 EDTBMYAlder Biopharmaceuticals regains worldwide rights to clazakizumab
Subscribe for More Information
06:45 EDTAZNAstraZeneca volatility elevated
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use